PHVS vs. GRFS, LVTX, MYNZ, NLSP, ONCSQ, PROC, QLI, LLY, NVO, and JNJ
Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), OncoSec Medical (ONCSQ), Procaps Group (PROC), Qilian International Holding Group (QLI), Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceutical preparations" industry.
Grifols (NASDAQ:GRFS) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
Grifols received 315 more outperform votes than Pharvaris when rated by MarketBeat users. However, 64.71% of users gave Pharvaris an outperform vote while only 55.95% of users gave Grifols an outperform vote.
In the previous week, Grifols had 1 more articles in the media than Pharvaris. MarketBeat recorded 2 mentions for Grifols and 1 mentions for Pharvaris. Grifols' average media sentiment score of 1.30 beat Pharvaris' score of 0.17 indicating that Pharvaris is being referred to more favorably in the news media.
Grifols has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.02, indicating that its share price is 402% less volatile than the S&P 500.
Grifols has a net margin of 0.90% compared to Grifols' net margin of 0.00%. Pharvaris' return on equity of 1.73% beat Grifols' return on equity.
Grifols has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Grifols currently has a consensus price target of $10.50, indicating a potential upside of 46.65%. Pharvaris has a consensus price target of $31.50, indicating a potential upside of 66.14%. Given Grifols' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Grifols.
Summary
Grifols beats Pharvaris on 10 of the 15 factors compared between the two stocks.
Get Pharvaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharvaris Competitors List
Related Companies and Tools
